Complete radiologic responses linked to T cell activity observed in two of first six evaluable patients IMV to host investor conference call and webcast on June 12, 2019 at 8:00 am ET IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today...
Mechelen, Belgium and Paris, France, 11 JUNE 2019, 07.00 CET – Servier and Galapagos NV(Euronext & NASDAQ: GLPG) completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule. ROCCELLA is a multi-regional, randomized,...
Maximize the amounts ones research site collects with financial audits. Best practices and simple strategies from an industry expert. FALLS CHURCH, Va., June 12, 2019 /PRNewswire-PRWeb/ — Maximize Your Clinical Trial Fees Put Financial Audits to Work for You **A...
New publication details findings from an industry collaborative workshop on facioscapulohumeral muscular dystrophy LEXINGTON, Mass., June 11, 2019 /PRNewswire-PRWeb/ — The FSH Society today announced that it has published a report on its recent workshop with...
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase...
Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint...
Email
Text